Safety-Net Hospitals Expected to Pay Full Price and Hope Pharma Pays Them Back, Wholesalers Rig the Drug Pricing Deck, and Three PBMs Graciously Control $200B in Specialty Revenue

Hey all, 

Happy Thursday! Welcome back to the industrial-strength comedy of errors we call the American pharmaceutical supply chain, where "market competition" is just three behemoths in a trench coat pretending they aren't also the ones writing the rules. Whether it’s PBM-affiliated pharmacies hoarding the revenue or wholesalers turning independent pharmacies into financial hostages via "compliance ratios," the message is clear: if you aren't the house, you're the one being played. It’s truly a testament to modern bureaucracy that we’ve managed to pivot the 340B program from a vital lifeline for social safety net hospitals into an administrative obstacle course designed to ensure drugmakers can "verify" their way out of helping the very people the law was intended to protect.

Enjoy the rundown!

Jacob Brody (Co-Founder & CEO, ZorroRX)

[Drug Channels] The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground

Drug Channels Institute’s 2025 analysis reveals that vertically integrated PBM-affiliated specialty pharmacies continue to dominate the sector, with the top three companies alone capturing two-thirds of the $293.4 billion in specialty dispensing revenues. While the number of accredited specialty pharmacy locations has grown to over 1,900, health systems have emerged as the fastest-growing participants by leveraging the 340B program to expand in-house operations. It’s a truly inspiring display of 'market competition' where three vertically integrated behemoths own the entire game while everyone else survives on the specialized scraps graciously left behind by their own PBM overlords.

Full Article

[Drugstore Cowboy] How Your Pharmacy Buys Drugs

The pharmaceutical distribution market is currently dominated by a massive triopoly that uses "Generic Compliance Ratios" and complex rebate structures to force independent pharmacies into rigid, high-volume purchasing commitments. These agreements function more like financial hostage situations, where pharmacists must navigate impossible generic-to-brand spending targets just to avoid the penalties that would otherwise bankrupt them. It’s a heartwarming masterclass in vertical integration where the wholesalers conveniently own the organizations meant to negotiate against them, ensuring the only thing "fixed" in the drug pricing game is the deck itself.

Full Article

[Fierce Healthcare] The 340B Rebate Pilot Program Rematch

The Health Resources and Services Administration (HRSA) is pushing a revised pilot program that would scrap 340B point-of-sale discounts in favor of a clunky rebate system, forcing safety-net hospitals to pay full price upfront and wait for drugmakers to pay them back. Recent stakeholder feedback reveals the pilot’s scope has nearly doubled, potentially saddling hospitals with over $1 billion in administrative costs and lost "float" money while safety-net providers already struggle with razor-thin margins. This shift effectively transforms the 30-year-old program from a direct subsidy for vulnerable patients into a bureaucratic obstacle course designed to protect pharmaceutical revenue. Because clearly, when Congress established 340B in 1992, their secret primary objective was ensuring that the "social safety net" they were protecting was actually the pharmaceutical companies’ right to determine for themselves which discounts they feel like paying and when.

Full Article